Summia Zaher1, Wladyslaw M Gedroyc, Lesley Regan. 1. Academic Department of Obstetrics and Gynaecology, Department of Radiology, Imperial College London at St. Mary's Hospital, Praed Street, London, W2 1NY, UK. s.zaher@imperial.ac.uk
Abstract
OBJECTIVE: To assess selection criteria used to determine eligibility for magnetic resonance-guided focused ultrasound surgery (MRgFUS) for the treatment of symptomatic uterine fibroids; to assess the percentage of patients suitable for MRgFUS. STUDY DESIGN: A retrospective analysis of 144 patients seeking minimally invasive treatment options for symptomatic uterine fibroids at a single treatment center. Clinical eligibility for MRgFUS was assessed at a gynecology clinic by a Gynecology research fellow trained in the procedure and suitability was assessed by magnetic resonance imaging. Several techniques were used to mitigate against factors that are contra-indications for MRgFUS. RESULTS: 100% of patients interested in MRgFUS were deemed clinically eligible for the procedure and 74% were deemed technically suitable to proceed with treatment. CONCLUSIONS: Mitigation techniques allow for less restrictive MRgFUS selection criteria for treatment for symptomatic uterine fibroids. These less restrictive criteria are expected to expand the pool of patients for whom MRgFUS is a viable treatment option for uterine fibroid symptoms.
OBJECTIVE: To assess selection criteria used to determine eligibility for magnetic resonance-guided focused ultrasound surgery (MRgFUS) for the treatment of symptomatic uterine fibroids; to assess the percentage of patients suitable for MRgFUS. STUDY DESIGN: A retrospective analysis of 144 patients seeking minimally invasive treatment options for symptomatic uterine fibroids at a single treatment center. Clinical eligibility for MRgFUS was assessed at a gynecology clinic by a Gynecology research fellow trained in the procedure and suitability was assessed by magnetic resonance imaging. Several techniques were used to mitigate against factors that are contra-indications for MRgFUS. RESULTS: 100% of patients interested in MRgFUS were deemed clinically eligible for the procedure and 74% were deemed technically suitable to proceed with treatment. CONCLUSIONS: Mitigation techniques allow for less restrictive MRgFUS selection criteria for treatment for symptomatic uterine fibroids. These less restrictive criteria are expected to expand the pool of patients for whom MRgFUS is a viable treatment option for uterine fibroid symptoms.
Authors: David Schlesinger; Stanley Benedict; Chris Diederich; Wladyslaw Gedroyc; Alexander Klibanov; James Larner Journal: Med Phys Date: 2013-08 Impact factor: 4.071
Authors: Esther V A Bouwsma; Gina K Hesley; David A Woodrum; Amy L Weaver; Phyllis C Leppert; Lisa G Peterson; Elizabeth A Stewart Journal: Fertil Steril Date: 2011-07-27 Impact factor: 7.329
Authors: Chung Y Kong; Lesley Meng; Zehra B Omer; J Shannon Swan; Serene Srouji; G Scott Gazelle; Fiona M Fennessy Journal: AJR Am J Roentgenol Date: 2014-08 Impact factor: 3.959
Authors: Marianne J Voogt; Marijn van Stralen; Marlijne E Ikink; Roel Deckers; Koen L Vincken; Lambertus W Bartels; Willem P Th M Mali; Maurice A A J van den Bosch Journal: Cardiovasc Intervent Radiol Date: 2011-12-07 Impact factor: 2.740